EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome

Alberto Diaz-Jimenez, Maria Ramos, Barbara Helm, Sara Chocarro, Dario Lucas Frey, Shubham Agrawal, Kalman Somogyi, Ursula Klingmüller, Junyan Lu, Rocio Sotillo

Drug Resistance Updates · 2024-05 · 74 · 101081

DOI: 10.1016/j.drup.2024.101081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-05. Verfasst von Alberto Diaz-Jimenez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; Ruprecht Karls Uni…. Hauptthemen laut MEDLINE: Lung Neoplasms, Anaplastic Lymphoma Kinase, src-Family Kinases, Proteome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, an unmet clinical need still to address is the treatment of refractory tumors that contain drug-induced resistant mutations in the driver oncogene or exhibit resistance through the activation of diverse mechanisms. In this study, we established mouse tumor-derived cell models representing the two most prevalent EML4-ALK variants in human lung adenocarcinomas and characterized their proteomic profiles to gain insights into the underlying resistance mechanisms. We showed that Eml4-Alk variant 3 confers a worse response to ALK inhibitors, suggesting its role in promoting resistance to targeted therapy. In addition, proteomic analysis of brigatinib-treated cells revealed the upregulation of SRC kinase, a protein frequently activated in cancer. Co-targeting of ALK and SRC showed remarkable inhibitory effects in both ALK-driven murine and ALK-patient-derived lung tumor cells. This combination induced cell death through a multifaceted mechanism characterized by profound perturbation of the (phospho)proteomic landscape and a synergistic suppressive effect on the mTOR pathway. Our study demonstrates that the simultaneous inhibition of ALK and SRC can potentially overcome resistance mechanisms and enhance clinical outcomes in ALK-positive lung cancer patients. ONE SENTENCE SUMMARY: Co-targeting ALK and SRC enhances ALK inhibitor response in lung cancer by affecting the proteomic profile, offering hope for overcoming resistance and improving clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAnaplastic Lymphoma Kinasesrc-Family KinasesProteomeProtein Kinase InhibitorsDrug Resistance, NeoplasmOrganophosphorus CompoundsAnimalsHumansMiceCell Line, TumorPyrimidinesProteomicsOncogene Proteins, FusionAdenocarcinoma of LungSignal Transduction

Stichwörter der Autor:innen

ALKLung CancerResistanceSRCTargeted therapy

Substanzen

Anaplastic Lymphoma Kinasesrc-Family KinasesProteomeProtein Kinase InhibitorsbrigatinibPyrimidinesALK protein, humanOncogene Proteins, FusionEML4-ALK fusion protein, humanAlk protein, mouse

Autor:innen und Institutionen

  • Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; Ruprecht Karls University of Heidelberg, Heidelberg 69120, Germany.
  • Division of Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Center for Lung Research (DZL) and Translational Lung Research Center…
  • Division of Systems Biology of Signal Transduction, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
  • Medical Faculty Heidelberg, Heidelberg University, Heidelberg 69120, Germany.
  • Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
  • Division of Molecular Thoracic Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; German Center for Lung Research (DZL) and Translational Lung Research Center Heidelberg…

Förderung

  • German Cancer Research Centre

Zitieren

APA

Diaz-Jimenez, A., Ramos, M., Helm, B., Chocarro, S., Frey, D. L., Agrawal, S., Somogyi, K., Klingmüller, U., Lu, J., & Sotillo, R. (2024). Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome. Drug Resistance Updates, 74, 101081. https://doi.org/10.1016/j.drup.2024.101081

Vancouver

Diaz-Jimenez A, Ramos M, Helm B, Chocarro S, Frey DL, Agrawal S, et al. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome. Drug Resistance Updates. 2024;74:101081. doi:10.1016/j.drup.2024.101081

BibTeX
@article{DiazJimenez2024,
  author = {Diaz-Jimenez, Alberto and Ramos, Maria and Helm, Barbara and Chocarro, Sara and Frey, Dario Lucas and Agrawal, Shubham and Somogyi, Kalman and Klingmüller, Ursula and Lu, Junyan and Sotillo, Rocio},
  title = {Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome},
  journal = {Drug Resistance Updates},
  year = {2024},
  volume = {74},
  pages = {101081},
  doi = {10.1016/j.drup.2024.101081}
}
Kostenlos starten →